Literature DB >> 27241103

Ovarian Cancer in Hereditary Cancer Susceptibility Syndromes.

Quentin B Nakonechny1, C Blake Gilks2.   

Abstract

Hereditary breast and ovarian cancer (HBOC) syndrome and Lynch syndrome (LS) are associated with increased risk of developing ovarian carcinoma. Patients with HBOC have a lifetime risk of up to 50% of developing high-grade serous carcinoma of tube or ovary; patients with LS have a 10% lifetime risk of developing endometrioid or clear cell carcinoma of the ovary. Testing all patients with tubo-ovarian high-grade serous carcinoma for mutations associated with HBOC syndrome, and all patients presenting with endometrioid or clear cell carcinoma of the ovary for mutations associated with LS can identify patients with undiagnosed underlying hereditary cancer susceptibility syndromes.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BRCA1; BRCA2; Hereditary cancer; Lynch syndrome; Mismatch repair; Ovarian carcinoma

Mesh:

Year:  2016        PMID: 27241103     DOI: 10.1016/j.path.2016.01.003

Source DB:  PubMed          Journal:  Surg Pathol Clin        ISSN: 1875-9157


  5 in total

1.  Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.

Authors:  Sandra Bonache; Irene Esteban; Alejandro Moles-Fernández; Anna Tenés; Laura Duran-Lozano; Gemma Montalban; Vanessa Bach; Estela Carrasco; Neus Gadea; Adrià López-Fernández; Sara Torres-Esquius; Francesco Mancuso; Ginevra Caratú; Ana Vivancos; Noemí Tuset; Judith Balmaña; Sara Gutiérrez-Enríquez; Orland Diez
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-10       Impact factor: 4.553

Review 2.  Role of Poly Adenosine Diphosphate Ribose Polymerase Inhibitors in Advanced Stage Ovarian Cancer.

Authors:  Ena Arora; Muhammad Masab; Vishal Jindal; Iqra Riaz; Sorab Gupta; Gabor Varadi
Journal:  Cureus       Date:  2018-05-24

Review 3.  Hereditary Gynecologic Cancer Syndromes - A Narrative Review.

Authors:  Stoyan Kostov; Rafał Watrowski; Yavor Kornovski; Deyan Dzhenkov; Stanislav Slavchev; Yonka Ivanova; Angel Yordanov
Journal:  Onco Targets Ther       Date:  2022-04-08       Impact factor: 4.147

Review 4.  Current Standards and Recent Advances in Biomarkers of Major Endocrine Tumors.

Authors:  Yanhong Luo; Hua Zhu; Tao Tan; Jianfeng He
Journal:  Front Pharmacol       Date:  2018-09-10       Impact factor: 5.810

Review 5.  A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review).

Authors:  Luca Falzone; Giuseppa Scandurra; Valentina Lombardo; Giuseppe Gattuso; Alessandro Lavoro; Andrea Benedetto Distefano; Giuseppe Scibilia; Paolo Scollo
Journal:  Int J Oncol       Date:  2021-06-16       Impact factor: 5.650

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.